Table 2.
Outcomes of patients on AS by group (n = 698)
| Baseline PSA >10 (n = 82) | PSA rise >10 (n = 157) | PSA ≤10 (n = 459) | p value | ||
|---|---|---|---|---|---|
| Median follow-up months (IQR) | 33.8 (20.4–59.1) | 53.9 (34.8–74. | 36.3(19.4–62.2) | 0.001 | |
| Median months to first repeat biopsy (IQR) | 13.7 (6.6–24.1) | 15.2 (7.6–28.4) | 12.3 (6.1–20.1) | 0.002 | |
| AH at first repeated biopsy (%) | 18 (21.7) | 43 (27.6) | 102 (22.3) | 0.37 | |
| AH at subsequent biopsy (%) | 9 (13.9) | 26 (23.0) | 68 (19.1) | 0.32 | |
| Reason for AH | Number of cores involved (%) | 9 (10.8) | 29 (18.6) | 62 (13.5) | 0.18 |
| Gleason score (%) | 12 (14.5) | 33 (21.2) | 70 (15.3) | 0.20 | |
| % core involvement (%) | 4 (4.8) | 16 (10.3) | 30 (6.6) | 0.20 | |
| Number who underwent treatment (%) | 32 (38.5) | 61 (39.1) | 135 (29.5) | 0.04 | |
| Number started on 5ARI (%) | 16 (19.3) | 29 (18.6) | 80 (17.5) | 0.89 | |
| Prostate mpMRI | |||||
| Cancer | 17 (20.7) | 31 (19.8) | 52 (11.3) | 0.002 | |
| No cancer | 5 (6.1) | 21 (13.4) | 34 (7.4) | ||
| No mpMRI | 60 (73.2) | 105 (66.9) | 373 (81.3) | ||
AS: active surveillance; PSA: prostate-specific antigen; IQR: interquartile range; TRUS: transrectal ultrasound; AH: adverse histology; 5ARI: 5-alpha reductase inhibitor; mpMRI: multi-parametric magnetic resonance imaging.